Head-to-head · free
DexCom, Inc. vs Genmab
DXCM vs GMAB — return on capital, cash generation, margins and balance sheet side by side.
DXCM
3 / 5
measures where DXCM leads
GMAB
2 / 5
measures where GMAB leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | DXCM · FY2025 | GMAB |
|---|---|---|
| Revenue | $4.7B | — |
| Net income | $836.3M | — |
| Revenue growth (yearly, multi-year) | 17.5% | — |
| Free cash flow | $1.1B | — |
| Free cash flow margin | 23.1% | — |
| Net cash / (debt) | — | — |
| ROIC | 15.8% | 10.1% |
| Return on equity | 34.5% | 17.5% |
| Gross margin | 60.1% | 93.6% |
| Operating margin | 19.6% | 33.6% |
| Net debt / EBITDA | 0.28x | 3.13x |
Figures are as reported by each company; latest fiscal year shown.
Where DexCom, Inc.'s cash went (FY2025)
- Capital spending
- $363.5M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free